ERN1 and cancer: Our study demonstrating that cancer cell-intrinsic activation of IRE1α signaling constitutes a driver of immunosuppression in the TME, suggests that targeting this ER stress sensor may represent a “two-pronged” therapeutic approach to restrain malignant cells, while concomitantly eliciting potent anti-cancer immunity.